ClinicalTrials.gg
CompletedNCT02303769GL2702Updated Feb 25, 2016

Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS

A Phase 3 interventional study of Tamsulosin HCL 0.4mg and Tamsulosin HCL 0.2mg in Benign Prostatic Hyperplasia, sponsored by GL Pharm Tech Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2016-02-25.

Sponsored by GL Pharm Tech Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.

Enrollment
17th of 48
309 · median 118
Started
2014
with 5 others
Phase 3
11 of 48
1 open now
Registered
23rd of 48
by date

Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 17th largest by enrollment, is one of 6 that started in 2014, is one of 11 in phase 3, and was the 23rd registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About tamsulosin

Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing tamsulosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

Study to investigate the efficacy and safety of GL2702 GLARS-NF1tablet and Harnal-D - tablet in benign prostatic hyperplasia patients with lower urinary tract symptomatic

Read the detailed description

GL2702 GLARS-NF1 tablet is controlled released formation which is made by GL Pharm Tech

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

Keywords

  • Lower Urinary Track Syndrome
  • Harnal
  • Tamsulosin HCL 0.4mg
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 50 years old, BPH diagnosted, Adult Male Subject
  • IPSS ≥ 13 point
  • PSA \< 4ng/mL
  • 5ml/sec \< Qmax ≤ 15ml/sec

Exclusion criteria

Exclusion Criteria:

  • Prostatic cancer
  • 250ml \< PVR
  • or AST > 2 times (Upper Normal Range)
  • Total > 1.5 times (Upper Normal Range)
  • Treated with α-adrenalin receptor blocker within 2weeks before screening
  • Treated with 5Alpha-Reductase Inhibitor within 6 months before screening
  • Treated with phytotherapy within 2weeks before screening
  • Treated with Anabolic Steroid within 6 months before screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
309 participants (actual)

Study arms

  • Active comparator
    Tamsulosin HCL 0.2mg

    Harnal-D tablet (Tamsulosin HCL 0.2mg)

    Drug: Tamsulosin HCL 0.2mg

  • Experimental
    Tamsulosin HCL 0.4mg

    GL2702 GLARS-NF1 tablet (Tamsulosin HCL 0.4mg)

    Drug: Tamsulosin HCL 0.4mg

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline to endpoint in total International Prostate Symptom Score

    Time frame: 8 weeks

Secondary outcomes

  1. Change from baseline to endpoint in total International Prostate Symptom Score

    Time frame: 4 weeks

  2. Change from baseline to endpoint in voiding score

    Time frame: 4 weeks, 8 weeks

  3. Change from baseline to endpoint in IPSS QoL

    Time frame: 4 weeks, 8 weeks

  4. Change from baseline to endpoint in Qmax

    Time frame: 4 weeks, 8 weeks

  5. Change from baseline to endpoint in PVR

    Time frame: 4 weeks, 8 weeks

  6. Time to event/proportion of subjects with AUR

    Time frame: 8 weeks

  7. Time to event/proportion of subjects undergoing BPH related prostatic surgery

    Time frame: 8 weeks

07

Study locations

1 site
  • Eulji general hospital
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of May 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2014
First posted
Dec 1, 2014
Start
Mar 2014
Primary completionActual
May 2015
CompletionActual
Oct 2015
Last update
Feb 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02303769
Lead sponsor
GL Pharm Tech Corporation
Responsible party
Sponsor
First posted
Dec 1, 2014
Start date
Mar 2014
Primary completion
May 2015
Completion
Oct 2015
Last update
Feb 25, 2016

Study contacts

You T Gun, MD
principal investigator · Eulji General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion